Publications by authors named "Negar Nejati"
Article Synopsis
- Primary bone tumors (PBTs) are rare but can lead to significant health risks, particularly due to their tendency to spread to the lungs, affecting survival rates based on tumor type and treatment options.
- Despite progress in treatment over the past 40 years, survival rates for PBT patients have not significantly improved, highlighting the need for new therapies.
- Current treatments include surgery, radiotherapy, and chemotherapy, with new promising immunotherapies like CAR-T cell therapy being explored to enhance patient outcomes in managing PBTs.
Article Synopsis
- - Despite being less common, T-cell malignancies are highly aggressive and typically have poor outcomes, prompting investigation into CD7-targeted CAR T cell therapy as a potential treatment option.
- - A systematic review of clinical trials showed an overall response rate of 100%, with high rates of stringent/complete responses (85%) and minimal residual disease negativity (85%), though there were notable hematological toxicities.
- - The results suggest that targeting CD7 in CAR T cell therapy is both effective and relatively safe for patients with relapsed or refractory T-cell cancers, with most adverse events being manageable.
Article Synopsis
- Pancreatic cancer (PC) is highly lethal with low survival rates, largely due to challenges like drug resistance and an immunosuppressive tumor microenvironment (TME).
- The TME, particularly the role of macrophages (M1 and M2 types), is crucial in tumor growth and progression, presenting an opportunity for new treatment strategies.
- Innovative therapeutic approaches targeting tumor-associated macrophages (TAMs) could enhance anti-tumor responses, improve chemotherapy efficacy, and potentially change the treatment landscape for pancreatic cancer.